The European Society for Medical Oncology (ESMO) Congress 2025 took place in Berlin, Germany, marking its 50th anniversary. Fast Five brings you key insights from leading experts, captured live at the Congress.
In this episode, Bertrand Tombal, Cliniques Universitaires Saint-Luc and Université catholique de Louvain, Belgium, discusses the latest updates in genitourinary cancers presented at ESMO 2025.
- Refining first-line therapy in PSMA-positive metastatic hormone-sensitive prostate cancer from the PSMAddition trial
- Perioperative immunotherapy plus chemotherapy in cisplatin-ineligible muscle-invasive bladder cancer from KEYNOTE-905
- ctDNA-guided adjuvant treatment in muscle-invasive bladder cancer from IMvigor011
Stay tuned for more in-depth coverage of the ESMO Congress in the upcoming EMJ Oncology Journal, publishing on 2nd December 2025.
Disclosure: Tombal has received grants from Astellas, Bayer, and Ferring, with payments to the institution; consulting fees from Amgen, Astellas, AstraZeneca, Bayer, Accord, Ferring, Novartis, and Janssen, with payments to the author; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amgen, Astellas, AstraZeneca, Bayer, Accord, Ferring, Novartis, and Janssen, with payments to the author.
